Effect of mutations in the PCSK9 gene on the cell surface LDL receptors
Top Cited Papers
Open Access
- 29 March 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 15 (9) , 1551-1558
- https://doi.org/10.1093/hmg/ddl077
Abstract
The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is involved in the post-transcriptional regulation of the low-density lipoprotein (LDL) receptors (LDLR). Mutations in the PCSK9 gene have been associated with both hypocholesterolemia and hypercholesterolemia through ‘loss-of-function’ and ‘gain-of-function’ mechanisms, respectively. We have studied the effect of the four loss-of-function mutations R46L, G106R, N157K and R237W and the two gain-of-function mutations S127R and D374Y on the autocatalytic activity of PCSK9, as well as on the amount of the cell surface LDLR and internalization of LDL in transiently transfected HepG2 cells. The two groups of mutations did not differ with respect to autocatalytic activity of PCSK9, but they did differ with respect to the amount of cell surface LDLR and internalization of LDL. The four loss-of-function mutations had a 16% increased level of cell surface LDLR and a 35% increased level of internalization of LDL as compared with WT-PCSK9. The two gain-of-function mutations had a 23% decreased level of cell surface LDLR and a 38% decreased level of internalization of LDL as compared with WT-PCSK9. Our studies have also shown that transfer of media from transiently transfected HepG2 cells to untransfected HepG2 cells, reduces the amount of cell surface LDLR and internalization of LDL in the untransfected cells within 20 min of media transfer. Thus, PCSK9 or a factor acted upon by PCSK9, is secreted from the transfected cells and degrades LDLR both in transfected and untransfected cells.Keywords
This publication has 11 references indexed in Scilit:
- Low‐density lipoprotein receptor activity in Epstein‐Barr virus‐transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 geneScandinavian Journal of Clinical and Laboratory Investigation, 2006
- Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemiaAtherosclerosis, 2005
- Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9Proceedings of the National Academy of Sciences, 2005
- Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartmentProceedings of the National Academy of Sciences, 2005
- NARC-1/PCSK9 and Its Natural MutantsJournal of Biological Chemistry, 2004
- Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse LiverJournal of Biological Chemistry, 2004
- The Modular Adaptor Protein ARH Is Required for Low Density Lipoprotein (LDL) Binding and Internalization but Not for LDL Receptor Clustering in Coated PitsPublished by Elsevier ,2004
- Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProceedings of the National Academy of Sciences, 2004
- Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genesProceedings of the National Academy of Sciences, 2003
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences, 2003